chirodoc, here is a short version of my reply to your questions on the Xoma thread. First, I am still digesting the ARRS/SQNA merger. I've owned these two in the past but have been out for a while. Arris has reinvented itself a few times, first with the Kephri acquisition to become a "protease inhibitor house" and now with Sequana to become ?? I used to like the old old guard of Michael Ross et al, but these guys have been gone since shortly after Kephri. Not sure what to make of the current people, although I know many think highly of Mr. Walker (hope I got the name right).
On Incyte, I am not sure if I can add much to what Rocketman has posted in the past. This was a "re-invention" that did work (boy, what an understatement) as the company went from a more or less classical so-so biotech to a very successful, to date, genomics/software hybrid. This appears to have been done at the right time and with exceptional execution. On MLNM, I like their science and overall business plan but have not spent a lot of time examining their management and/or decision making.
PB
P.S. MLNM thanked to the 12-15 range after the ChemGenics acquisition; maybe you'll get lucky and Axys (?) will recover, just as MLNM did, after the dust settles. |
